about
Celecoxib for rheumatoid arthritisSelf-management education programmes for rheumatoid arthritisAssociation of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritisEffect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexateEnigma of IL-17 and Th17 Cells in Rheumatoid Arthritis and in Autoimmune Animal Models of ArthritisRecent insights into the role of autophagy in the pathogenesis of rheumatoid arthritisFrom the model of integral attention to the creation of centers of excellence in rheumatoid arthritisEducation for patients with rheumatoid arthritis in Latin America and the CaribbeanSpanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritisMeasures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds EnUse of RNA sequencing to evaluate rheumatic disease patientsNanomedicine delivers promising treatments for rheumatoid arthritisClinical biomarkers and pathogenic-related cytokines in rheumatoid arthritisPeptidylarginine deiminase and protein citrullination in prion diseases: strong evidence of neurodegenerationNew insights into the impact of neuro-inflammation in rheumatoid arthritisDietary Phytochemicals: Natural Swords Combating Inflammation and Oxidation-Mediated Degenerative DiseasesRheumatoid arthritis: identifying and characterising polymorphisms using rat modelsThe Role of Posttranslational Protein Modifications in Rheumatological Diseases: Focus on Rheumatoid ArthritisCausal modeling using network ensemble simulations of genetic and gene expression data predicts genes involved in rheumatoid arthritisHuman genetics in rheumatoid arthritis guides a high-throughput drug screen of the CD40 signaling pathwayGenome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritisA metabolically-stabilized phosphonate analog of lysophosphatidic acid attenuates collagen-induced arthritis2-hydroxy arachidonic acid: a new non-steroidal anti-inflammatory drugPlasma levels of IL-37 and correlation with TNF-α, IL-17A, and disease activity during DMARD treatment of rheumatoid arthritisGlycyrol suppresses collagen-induced arthritis by regulating autoimmune and inflammatory responsesMucosal-associated invariant T cell is a potential marker to distinguish fibromyalgia syndrome from arthritisChallenges and treatment options for rheumatoid arthritis during pregnancy.The role of the prolactin/vasoinhibin axis in rheumatoid arthritis: an integrative overview.Transforming growth factor β 869C/T and interleukin 6 -174G/C polymorphisms relate to the severity and progression of bone-erosive damage detected by ultrasound in rheumatoid arthritisRandomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial.Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: long-term real-life data from the Lorhen Registry.High levels of metastasis-inducing S100A4 protein and treatment outcome in early rheumatoid arthritis: data from the PERAC cohort.Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study.Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data.A systematic review of randomised controlled trials in rheumatoid arthritis: the reporting and handling of missing data in composite outcomes.Apps for People With Rheumatoid Arthritis to Monitor Their Disease Activity: A Review of Apps for Best Practice and Quality.Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis.Tocilizumab-induced remission of nephrotic syndrome accompanied by secondary amyloidosis and glomerulonephritis in a patient with rheumatoid arthritisModels solely using claims-based administrative data are poor predictors of rheumatoid arthritis disease activitySafety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants
P2860
Q24186209-D5FBF26D-30F9-4865-846D-54C906D66209Q24193309-E88EEF96-2D9B-42EF-B290-DF29A4F16E70Q24289540-B6514460-E0A7-4D6C-8571-36E77D5591BDQ24658507-85DF41C2-933E-4204-8741-924B13AE0893Q26768254-54CE9BF8-C1A4-4C04-B4E2-6EB8550602DAQ26784021-52B2DCFA-FABF-4096-80BA-A4884E7FCD5AQ26799799-CBB33DCD-F663-42F5-9A89-530D7CB85ADAQ26800141-F060CE07-4F42-45EB-9E70-FCA79166B264Q26852081-7DF50C81-F9F9-4E9F-908E-1B182D7B681EQ26862017-1187A7D3-AB57-46A3-82EF-8C0281AF767BQ26864197-6BB1C6C4-811A-41A6-938D-7F44FBAD94C0Q27021438-2014AA09-FFFA-4AA8-9940-EAACCCC8706BQ27022559-3B3504D6-10E6-4D70-8D4F-7BE9D8DEEB5FQ27023431-2A180DFF-494E-4C87-B9F4-BE54D9159015Q27023946-DBB18585-02D8-4DFD-AF02-ABB1579CD7CAQ28067382-8866630F-5330-416E-AB8A-17CBB89015E0Q28073099-1ADDC2E1-73A5-49FA-A268-6FFEA1822D4FQ28395318-125E1D4F-03C6-4160-A0F6-F7E01EDDEDA7Q28477388-570D9742-2398-4B9D-A171-CC3C59C667DBQ28488150-5DB0FE3E-4AE4-4707-8A0A-CE40887557BBQ28489093-1756E212-DB3B-444C-A5BE-2C7D3D992EA8Q28534911-E17BD983-D8C9-4532-BDD5-EF6C51FF357DQ28535742-E34D5BAC-600A-438E-9BF5-E41F215E3BEBQ28538381-2FC91A34-8C5A-43D3-A060-CBAA8E69EF8CQ28540896-10A08CED-64C2-47E6-AB3C-B460A4833046Q28545955-3029343B-B0DE-46F1-8F2D-9BC331BFC912Q30249730-CD2970B8-B5E0-4571-A936-599234BC21DFQ30251689-44CE5B12-35FB-4112-9D27-EC49B6B35986Q30472063-7F0E0445-518B-411E-8591-92F32635BE6EQ30812918-EA70C6B4-F03D-4499-A4F5-B2A2646C99A2Q30841797-F2DAFD95-7DB7-4397-A839-11C85F33B0CEQ30876263-632C8348-60BB-4005-8E49-5FED10B2FAAFQ30882161-7B4330D5-F844-48FD-A40A-0C9D61295B04Q30984829-3DA0261A-CCE1-4610-8999-583A438D191AQ31105054-D1370B95-8149-4FC4-93FB-D1B6F9D129A8Q33452891-681BE3F2-AAFE-49AA-8587-6D5668224373Q33638048-1B1DF55B-8D80-4BC3-97B9-38DBF6F6656DQ33639788-30A04F6D-5413-4CDC-AD53-898FA3DF5881Q33651231-D69E250F-344A-4F3A-AE4A-E72D990AD7E4Q33653945-F51C3A4D-9CDF-40BC-8256-736A98ACB590
P2860
description
article publié dans la revue scientifique The Lancet
@fr
im September 2010 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published in The Lancet
@en
наукова стаття, опублікована у вересні 2010
@uk
ശാസ്ത്രപ്രബന്ധം
@ml
name
Rheumatoid arthritis
@en
type
label
Rheumatoid arthritis
@en
prefLabel
Rheumatoid arthritis
@en
P2093
P1154
2-s2.0-85058158182
P1433
P1476
Rheumatoid arthritis
@en
P2093
David L Scott
Frederick Wolfe
Tom W J Huizinga
P304
P356
10.1016/S0140-6736(10)60826-4
P407
P5530
P577
2010-09-01T00:00:00Z
P6179
1100897725